Aurobindo Pharma Limited is recalling approximately 1,725 units (totaling 1,724.8 kilograms) of Irbesartan Bulk Active Pharmaceutical Ingredient. This bulk ingredient, which is used to manufacture blood pressure medication, was found to contain N-Nitrosodimethylamine (NDEA), a substance classified as a probable human carcinogen. The recall was initiated after testing detected the presence of this impurity in the active ingredient produced at the company's facility in India. While this recall involves bulk material distributed to a pharmaceutical manufacturer rather than finished tablets directly to consumers, it affects the safety of the final medication produced from these batches.
The product is contaminated with N-Nitrosodimethylamine (NDEA), which is a known environmental contaminant and a probable human carcinogen. Long-term exposure to levels of NDEA above acceptable limits may increase the risk of developing cancer.
Return unused product to place of purchase.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.